Search results
Showing 1 to 9 of 9 results for selinexor
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Awaiting development [GID-TA10694] Expected publication date: TBC
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]
In development [GID-TA10969] Expected publication date: 15 October 2025
In development [GID-TA11201] Expected publication date: TBC
In development [GID-TA11203] Expected publication date: TBC
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.